Kwan Goo Edmond (Ed) Cho, an industry veteran with a broad depth of experience in life sciences and pharmaceuticals, has become President of Harlan Korea.
Cho will have responsibility for all aspects of the Harlan Contract Research Services (CRS) business serving the Korean chemical, agrochemical and pharmaceutical markets.
Prior to joining Harlan CRS, Cho was Director of Market Access and Business Development for Zuellig Pharma Korea, a US$8bn subsidiary of the Zuellig Group, which provides contract services and clinical reach to multinational companies in more than 15 countries. He also held sales, marketing and management positions of increasing responsibility during 14 years with LG Life Sciences.
